SOPHiA GENETICS (SOPH) said Monday it expanded its collaboration with AstraZeneca (AZN) to deploy the MSK-ACCESS liquid biopsy testing application to 30 clinical institutions globally within the year.

The test is designed to detect actionable genomic alterations from a single blood draw, analyzing circulating tumor DNA to aid in real-time cancer monitoring and treatment selection, the company said.

The expanded roll-out will allow the two companies to further understand how liquid biopsy testing can complement solid tissue testing, SOPHiA said.